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Abstract: The development of a patient-centered approach to medicine is gradually allowing 
more patients to be involved in their own medical decisions. However, this change is not hap-
pening at the same rate in clinical research, where research generally continues to be carried 
out on patients, but not with patients. This work describes the why, when, and how of more 
active patient participation in the research process. Specific measures are proposed to improve 
patient involvement in 1) setting priorities, 2) study leadership and design, 3) improved access 
to clinical trials, 4) preparation and oversight of the information provided to participants, 
5) post-study evaluation of the patient experience, and 6) the dissemination and application of 
results. In order to achieve these aims, the relative emphases on the ethical principles underlying 
research need to be changed. The current model based on the principle of beneficence must be 
left behind, and one that upholds the ethical principles of autonomy and non maleficence should 
be embraced. There is a need to improve the level of information that patients and society as a 
whole have on research objectives and processes; the goal is to promote the gradual emergence 
of the expert patient.
Keywords: patients, research, clinical trials, bioethics, engagement
Introduction
Patients are gaining a more active role in health care systems. The move toward 
patient-centered medicine aims to provide the best health care for each individual patient, 
taking his or her goals, preferences, and values into account.1 Doctor–patient rela-
tionships are changing, and concepts such as shared decision making and patient 
empowerment2 are becoming a reality.
Patient advocacy groups now claim that their opinions must have greater influence 
on the decisions that affect them, which is reflected in the phrase “nothing about me 
without me”. The development of new health care management models where patients 
become clients and the enormous expansion of information technology are additional 
factors that contribute to accelerate this change.3 Patient-centered medicine cannot be 
practiced without patients participating in their own health care decisions and in the 
research that informs such decisions.4
Although this cultural shift is beginning to change the way we understand health 
care, it is not having the same impact on the research process.5 This may be because 
society does not see patient responsibility to participate in research as obvious as the 
responsibility to participate in their own medical care.4 According to the predominant 
culture, research is performed on patients, not with patients.6 Thus, patients continue 
to be regarded as a source of data and not as the true protagonists in the process. 
Initiatives have been developed in recent years to change this situation, but quite often 
Correspondence: José A Sacristán
Medical Department, Lilly Spain, Avda 
de la industria 30, 28108 Alcobendas, 
Madrid, Spain
Tel +34 91 663 5284
Fax +34 91 663 5231
email sacristan_jose@lilly.com 
Journal name: Patient Preference and Adherence
Article Designation: Review
Year: 2016
Volume: 10
Running head verso: Sacristán et al
Running head recto: Patient involvement in clinical research
DOI: http://dx.doi.org/10.2147/PPA.S104259
 
Pa
tie
nt
 P
re
fe
re
nc
e 
an
d 
Ad
he
re
nc
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
0.
24
4.
13
8.
15
5 
on
 1
3-
O
ct
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Patient Preference and Adherence 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
632
Sacristán et al
these end up being merely tokenistic.7 This paper analyzes 
the reasons why patients should be more actively involved 
in research and designates the phases in which they could 
participate (Figure 1). Moreover, there are specific examples 
of how patients can achieve the level of true partnership in 
the research process.
Identifying research priorities
The fact that the questions of clinical research are scientifi-
cally relevant does not necessarily mean that they are relevant 
from the patient’s perspective.5 Although patients should play 
an active role in setting research priorities, such participation 
continues to be the exception rather than the rule.8,9 Patient 
involvement is essential for achieving true translational 
research.10 Nevertheless, most research questions are posed 
from a medical or regulatory perspective, and they are often 
based on what has been called the “culture of the laboratory”, 
which is excessively focused on basic science and often 
removed from the true needs of patients.11,12
The Patient-Centered Outcomes Research Institute13 in the 
USA and the James Lind Alliance (www.lindalliance.org)14 
in the UK have outlined the differences in research priorities 
between doctors and patients and instituted measures to ensure 
that patients participate in the process. The Patient-Centered 
Outcomes Research Institute has started to include patients in the 
review and prioritization of its research projects,13 and the aims 
of the James Lind Alliance include the creation of a database of 
the principal uncertainties surrounding medical treatments (UK 
DUETs -database of uncertainties about the effects of treatments). 
These uncertainties are classified as known–unknown, in order 
to establish where new evidence would need to be generated, 
and which uncertainties already lend themselves to a systematic 
review of current evidence.15 The Alliance studies have been 
based on systematic prioritization devised jointly by patients, 
caregivers, and clinicians. The results have made clear that 
aspects related to real-life management of disease matter most 
to patients. For example, in a study performed on patients with 
asthma, the top priorities were management of the adverse 
effects associated with bronchodilator treatment and manage-
ment of asthma associated with other health conditions.12 The 
identification and proper handling of patient needs in clinical 
research will yield advantages in terms of clinical and economic 
benefits. It has been estimated that up to 80% of the expense 
involved in gathering evidence in research could be avoided.16 
Considering patients’ priorities could contribute to more effi-
cient clinical research.
Leading and designing research
Although it is not yet common practice, some patient associa-
tions have begun to lead research projects.17 The increasing 
development of health social networks and crowd-sourced 
studies has enabled organizations such as PatientsLikeMe and 
23andMe to promote research projects led by patient groups.18 
There are actually several examples of studies that use this 
method.19 The proliferation of these networks, based on the 
altruistic transfer of personal data by patients, requires proper 
handling in terms of privacy and data protection.
Patient involvement is crucial for identifying the ques-
tions to ask and the outcomes to assess,4 therefore it is 
increasingly common to involve patients or patient advocacy 
groups on study design.20–22 This involvement could help 
to achieve more relevant results, while at the same time 
Figure 1 How to engage patients in clinical research?
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improving patients’ recruitment and retention. Conducting 
comparative effectiveness research20 based on real-life data, 
long-term follow-up, comparisons with best current treat-
ments, greater emphasis on individualized treatment, and, 
most of all, selection of variables relevant to patients or 
patient-reported outcomes (PROs)21 should become a priority 
for patients engaged in study design.22
It has been stated that .75% of patients with diabetes 
would prefer that clinical trials include variables that mea-
sure the impact of the disease on their quality of life, such as 
the onset of kidney failure and dialysis, or blindness, rather than 
surrogate variables such as HbA1c.23 In oncology, there are 
examples that demonstrate the advantages of including patient-
experience end points and not only the traditional survival-
based end points.24 There are similar examples for other 
diseases.23,25–27 Worthy of special mention is the OMERACT 
(Outcome Measures in Rheumatoid Arthritis Clinical Trials) 
project, which has demonstrated the benefits of increasing 
involvement of patients with rheumatologic diseases in the 
design of clinical trials, particularly pertaining to identification 
of variables that matter to them.27 It is encouraging that the 
regulatory agencies have already taken some steps to ensure the 
participation of patients in study design on the assumption that 
without this perspective the risk-benefit trade-off analysis for 
new pharmaceuticals would be incomplete.
Although an increasing number of clinical studies include 
them, the use of PROs, defined as “any report of the status of a 
patient’s health condition that comes directly from the patient, 
without interpretation of the patient’s response by a clinician or 
anyone else”28 is still limited.29 Only 18% of clinical trials in the 
area of diabetes30 and 16% of trials in the cardiovascular field31 
include PROs. Likewise, fewer than 30% of drug data sheets 
include PROs.32,33 The development of guidelines by regulatory 
agencies on the inclusion of PROs in the evaluation of new 
drugs34 will probably increase their use in the coming years.
To be useful in clinical research, PROs must be relevant 
and adequately validated.35 Unfortunately, this has not been 
the case with many of those used in research36,37 and the scales 
continue putting too much emphasis on symptoms. Simple 
and easily measurable PROs based on objective metrics38 
that go beyond the mere symptoms of the disease must be 
developed and utilized. These must evaluate aspects such 
as quality of life and functional status, using global ratings 
provided by the patients themselves.32 The development of 
computerized health applications (apps) can facilitate the use 
of PROs. However, it must be ensured that such applications 
actually measure what they are intended to measure39 and 
that they are adequately regulated.40
Improving access to clinical trials
If participation in clinical research is a societal obligation,41 
then the ability to do so should be a patient right. More than 
70% of the general population believes that patients need 
more opportunities to participate in clinical trials.42 In spite 
of this, only a small portion of patients who could participate 
in a clinical trial are able to do so. Participation in clinical 
trials typically does not exceed 5% of patients with cancer.42 
This is because only those patients whose doctors are also 
investigators participate in clinical trials. The final aim of 
everyone involved in the development of clinical trials and of 
health care systems that seek excellence should be to enable 
all patients who meet the selection criteria to participate in 
research, if they desire to do so.
Access for more patients, and for patients with different 
perspectives, would speed up obtaining relevant knowledge 
and results that are more applicable to heterogeneous groups 
of patients. Access to research is influenced by socioeco-
nomic, racial, and ethnic factors and by the type of health 
insurance.43,44 Programs to prevent such disparities should 
be set up to ensure that all patients who wish to participate 
in clinical trials can do so. It would be very beneficial for 
improving patients’ access to clinical research to enhance 
and systematize information about ongoing studies and 
about the sites participating in them. Patient associations 
should receive this information so they can pass it along 
with their associates. In addition, opportunities offered by 
new technologies should not be neglected. In this regard, 
clinical trial databases should include information about 
the characteristics of ongoing studies as well as details 
about the participating sites. There are already several drug 
agencies (eg, www.clinicaltrialsregister.eu in the European 
Union) that include such information. Recent initiatives, 
such as Trials4Me (http://trials4me.lillycoi.com/) which 
uses Google Maps to locate sites participating in clinical 
trials from the Clinicaltrials.gov database, will greatly 
facilitate patient searches. Just as there is a unified reference 
database for clinical trials (ClinicalTrials.gov), a platform 
should be created with unified and standardized information 
directed to patients.
The growing development of learning health care systems 
should give rise to “point of care research”, where clinical 
research is embedded into clinical practice.45,46 A large 
number of patients could have access to comparative effec-
tiveness studies in which health interventions used in normal 
clinical practice are evaluated. This would contribute not 
only to the more efficient generation of new and relevant 
knowledge for patients but also to a speedier application 
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of the results. The enormous development of electronic 
health records and information technologies could help in 
carrying out randomized database studies47 (or randomized 
registry trials), a method recently termed “the next disruptive 
technology” in clinical research.48 This method proposes the 
integration of research modules into usual clinical practice 
in order to combine the main strengths of randomized con-
trolled trials (ie, initial randomization) and registries (ie, 
naturalistic follow-up). Obviously, in order for the develop-
ment of big data to achieve its full potential, high-quality 
data with the end purpose of improving health care results 
in individual patients must be collected in medical practice 
and in research.49
Adequate information about the 
study
It must be ensured that patients receive all the informa-
tion they need to make a free and informed choice before 
consenting to participate in a study. The informed consent 
should constitute the means by which the principle of 
autonomy is applied. For the process to work properly, 
the information provided to patients must be complete, rel-
evant, and easy to understand. Frequently, both the informed 
consent document (ICD) and the patient information sheet 
are excessively long documents that are difficult to read 
and understand.50,51 Because of this, ∼30% of participants 
are unaware of basic aspects of the research, such as the 
existence of random assignment, the possibility that they 
will be assigned to placebo, the fact that adverse effects 
could occur during the study, and even the availability of 
an insurance policy.52,53
The ICD needs to be restored to its basic function, which 
is to ensure that patients have suitable information, not only 
about the overall aims of clinical research but also about 
the aims and characteristics of the study, its potential risks 
and benefits, and the option of withdrawing from it if they 
so desire. For this to happen, the informed consent process 
should no longer be viewed as an administrative require-
ment, which is intended to protect the researchers more than 
the patients themselves.54 According to the new Regulation 
of the European Parliament on Clinical Trials on Medical 
Products for Human Use, the written information provided 
to the trial subjects or their legal representatives to obtain 
informed consent “shall be kept comprehensive, concise, 
clear, relevant, and understandable to a layperson”.55
It is essential for participants to understand that the pur-
pose of clinical research is to generate useful information for 
future patients and not necessarily to achieve a therapeutic 
benefit, since this cannot be guaranteed. Nevertheless, many 
patients participate in clinical trials because of the trust that 
they have in their doctors and the assumption that their 
participation will give them access to better treatments. This 
therapeutic misconception56 leads many patients (as well as 
many researchers) to confuse research with medical care and 
to tend to overestimate the potential benefits of participating 
in clinical trials. Although there are times when participation 
in a clinical trial is the only way in which a patient who has 
failed with other alternatives can access a new, potentially 
more effective medication,57 systematic reviews offer no 
evidence that clinical trial participants achieve better out-
comes than nonparticipants.58
There are few examples of studies where the opinion of 
health care system users has been considered to improve 
the design and readability of the patient information sheets 
included in clinical trials.59 It would be highly advisable for 
patients to participate in ethical discussions related to the 
studies to make sure that the information provided is clear 
and accessible. As pointed out earlier, this participation 
could be achieved not only by having patients involved in 
study design but also through the participation of patient 
representatives in the Institutional Review Boards (IRBs). 
Although IRB members support the participation of patients 
in their membership lists,60 very few IRBs actually put this 
into practice. Often, for practical reasons, the non-health 
care professionals who belong to IRBs are members of the 
hospital administration.60 In this regard, the new European 
Regulation for clinical trials represents a positive step for-
ward, as it55 explicitly establishes that “Member States should 
ensure the involvement of laypersons, in particular patients or 
patients’ organizations”. Although in theory any citizen could 
represent the interests of patients, the fact that one is or has 
been a patient could be an additional advantage, provided of 
course that the individuals in question are highly motivated 
and have a sufficient educational level.
It has been suggested recently that, for comparative effec-
tiveness studies on interventions in normal clinical practice, 
a simplified ICD could be used, similar to the one for medical 
care, or that the ICD could even be dispensed with.61 In the 
case of these “low-intervention clinical trials”, the European 
Regulation recognizes the need to adapt the ICD,55 so patients 
could play an important role in the review and evaluation of 
these simplified documents. They could also participate in 
the design of decision aids that would help to ensure that the 
consent granted by the patients is truly informed.62,63
Assessing patients’ experience
Carrying out a clinical trial is an enormously complex pro-
cess. There are often problems with recruiting or retaining 
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patients, which can make the process even more drawn out 
and expensive. Once the study is complete, it would be of 
great value to know about the opinions and experiences of the 
participants, so future studies could be designed better and 
achieve greater acceptance by doctors and patients.64,65
There have been several studies evaluating the experi-
ences of patients who have participated in clinical trials. In a 
survey covering ∼5,000 patients who had taken part in clinical 
trials at 15 research sites supported by the National Institute 
of Health, 73% of the participants rated their experience with 
a score of 9 or 10 on a 10-point scale. In addition, 97% stated 
that they would definitely or probably recommend a clinical 
trial to a friend or relative.66 These results are similar to those 
from another study of patients with depression, in which 87% 
of those interviewed were glad that they had participated in 
the clinical trial and 75% stated that they would be willing to 
participate again in the future.64 Approximately 30% of the 
patients in the latter study stated that their participation had 
increased their trust in their doctors. These and other surveys 
indicated that one of the main motivations of patients in 
participating in clinical trials is their willingness to help future 
patients (with percentages higher than 90%).64,67 This should 
be a powerful argument for overcoming the therapeutic 
misconception and the underlying hidden paternalism.
Despite these positive results, there are several areas that 
need improvement. In the previously mentioned study,66 
those surveyed indicated that the ICD did not contain enough 
details about the study (20%) or about the risks (19%). They 
said that it had been difficult for them to understand the 
content (22%), that they had not had enough time to think 
over their decision before signing the ICD (21%), or that they 
had received some form of pressure from the research staff 
to participate (6%). In another study, participants mentioned 
problems with describing their experiences in the question-
naires that were included in the clinical trial.68 Most likely, 
the patient experiences with respect to participation in clinical 
trials may vary with factors such as educational level, age, 
the trial phase, or the disease under study. It would therefore 
be advisable to collect these experiences in a systematic way 
to identify the problems and propose solutions adapted to 
each circumstance.
Informing participants about study 
results
According to some surveys, ∼95% of patients69 and members 
of IRBs70 believe that patients should be informed of the results 
of the research study. Nevertheless, this is a fairly uncommon 
practice, and the usual situation is that after participating in 
a study, patients are not notified of the results.71
The reasons offered for not informing patients have to do 
with their supposed desire to not know the results and with 
the possible anxiety that these results could cause. Then there 
is the difficulty, in practice, of communicating the results 
or ethical conflicts that a negative result could involve for 
the doctor in his dual role as physician and investigator.71 
However, it would seem to be an ethical standard, dictated 
by respect for the participants, to thank them for their partici-
pation and to provide them with the aggregate study results 
before they are made public to the scientific community.72 
Although informing patients of individual results is a matter 
of controversy, it could be justified by the same favorable 
arguments used to support disclosing aggregate results.73 
Fortunately, the 2013 update to the Declaration of Helsinki 
states, for the first time, that patients should have the option to 
receive information about the overall results of the study.74
From a logistics standpoint, giving the participants 
information about the results is a relatively easy require-
ment to implement. It would involve merely including this 
option on the information sheet given to subjects when they 
are invited to participate in the study, and at the same time 
establishing how the results will be communicated at the 
end of the study to those participants who want them.72,73 
Patients would have to be offered a summary of the aggre-
gate results in understandable language. This would detail 
the most important results, their implications, the possible 
long-term effects that are foreseen, and how the results will 
be communicated to the scientific community. Whether the 
results are positive or negative, it is important for patients to 
know if the study yielded new information and was useful 
for the advancement of knowledge.
Several studies have evaluated the satisfaction of patients 
with different ways of communicating results. In one of these, 
most of the patients (80%) chose to receive the information 
in a letter.75 Positive experiences have also been reported 
with presentations made by the investigator to a group of 
patients.76 It would seem that patients prefer to receive the 
information in a more personalized manner, for example, in 
a telephone call, rather than impersonally via the sponsor’s 
press release.77 These differences suggest that, ideally, an 
attempt should be made to communicate the results in a way 
that fits the preferences of the participants.
Disseminating and applying 
research findings
The study results should be communicated not only to the 
study participants but also to the wider public. This obligation 
is stated in the previously mentioned European Regulations 
on clinical trials. In 2013, the European Agency upgraded the 
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EudraCT database to enable sponsors to enter result-related 
information from clinical trials, in line with guidance from 
the European Commission. Since 2014, with the launch of 
a final iteration of EudraCT, it is mandatory for sponsors to 
make publicly available the details of the study, including 
a summary of the results. Such information should use the 
language understandable by the general public and be pre-
sented in simple and accessible formats. It would be highly 
advisable to have patients involved in the preparation of 
these documents.
There should also be mention of the initiatives by some of 
the scientific journals, such as the Annals of Internal Medicine 
and the Journal of the American Medical Association, which 
publish “summaries for patients” and brief and approachable 
reviews of common diseases and their treatments. An addi-
tional step has been taken by the British Medical Journal, 
which is heading a major campaign to promote and accelerate 
patient participation in the various areas of the health care 
field. For example, they have included patients in the peer 
review process for research articles.78
Although the purpose of research is to generate new 
knowledge that is able to improve outcomes for future 
patients, many of the results of research are never put into 
practice or are not implemented for many years. It requires 
an estimated average of 17 years for only 14% of new dis-
coveries to enter into daily clinical practice.79 It is of little 
use, and indeed would be unethical, to involve patients in 
research and ask them about their experiences if these are 
not used to improve care.80 The experiences of patients 
(eg, through PROs) should be included not only in regula-
tory documents (eg, drug data sheets) but also in clinical 
practice guidelines. Patient preferences are an essential 
component in the health care personalization process. 
There are already guidelines in which recommendations 
are established on the basis of such preferences.81 Patient 
participation with the groups of experts who prepare these 
clinical guides would ensure that patient perspectives and 
preferences are considered.
To achieve greater transparency in the research process, 
some initiatives have been launched aimed at improving the 
dissemination of research results. In spite of the potential 
risks involved,82 there are unquestionable advantages to 
the development of an open scientific approach in which 
“data sharing” is the norm.83 From the standpoint of society, 
such an approach could generate greater confidence in the 
results of research, improving clinical trial participation 
and funding.84 The Institute of Medicine has established 
recommendations for “guide sharing of clinical trial data”.85 
In addition, the European Medicines Agency86 has pub-
lished standards for promoting transparency and the dis-
semination of research results and allows different interest 
groups to request data from studies. Surprisingly, in the past 
4 years, only 5.5%, 1.5%, and 0.5% of requests for access 
to European Medicines Agency documents were submitted 
by the general public, patient organizations, and nonprofit 
organizations, respectively.86 It would not be surprising if 
the growing interest in research by patient organizations, 
many of which already have their own scientific advisors, 
were to generate an increase in requests for access to 
patient data.
Information and education: the 
expert patient
The earlier sections discussed the why, when, and how of 
active patient participation in research. However, there are 
two requirements to be met for all of these proposals to be 
implemented: 1) society must be much better informed on the 
aims and processes of clinical research and 2) the concept of 
the “expert patient” must be developed. Regarding the first 
requirement, there is a need to normalize society’s image 
of research. The general public’s scant familiarity with the 
basic aspects of research, and the fact that such familiarity 
tends to focus on the most negative aspects of research, 
contributes to it being perceived with a certain degree of 
suspicion and even fear.
Health care professionals, regulators, communication 
media, patient associations, and pharmaceutical companies 
need to collaborate to provide proper information about 
the purposes of research and the mechanisms available to 
protect participants. Society must realize that there is no 
progress without research, and that without patient par-
ticipation in current studies, there can be no new knowl-
edge to benefit future patients. For the same reason, we 
owe our current advantages of many medical advances 
to patients who participated in clinical trials in the past. 
The development and dissemination of campaigns in the 
media and educational materials can be of great help. The 
web pages of regulatory agencies such as the US Food and 
Drug Administration (http://www.fda.gov/ForPatients/
ClinicalTrials/default.htm), national health institutes, 
such as the NIH in the USA (http://www.nih.gov/health/
clinicaltrials/index.htm), and scientific associations such 
as the American Society of Clinical Oncology (http://
www.cancer.net/) include patient-directed information 
on the basic principles of clinical research. Similarly, 
some very interesting initiatives have emerged, such as 
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Healthtalkonline (http://healthtalkonline.org/), supported 
by Oxford University, that include videos in which actual 
patients relate their experiences with clinical trials and 
clarify certain basic aspects of the research process.
Second, many of the proposals made in this paper will 
not be feasible unless they include expert patients.87 This 
concept, based on the idea that implementation of edu-
cational and self-care programs could help patients with 
chronic diseases who take an active role in managing their 
own conditions,88 applies to the field of clinical research. 
Preparing patients to be experts in research will require an 
investment in their education. Of particular note here are the 
training courses offered by the European Patients’ Academy 
on Therapeutic Innovation (EUPATI), a consortium of 30 
European organizations dedicated to providing information 
and resources on medical research to individuals affected 
by various diseases. The expert course has been designed to 
teach patients or their family members all about the clinical 
trial process, from preclinical research all the way through 
regulatory approval. The course consists of six training 
modules: 1) discovery of medicines and planning of medi-
cine development; 2) nonclinical testing and pharmaceutical 
development; 3) exploratory and confirmatory clinical devel-
opment; 4) clinical trials; 5) regulatory affairs, medicinal 
product safety, pharmacovigilance, and pharmacoepide-
miology; and 6) health technology assessment principles 
and practice. The purpose is to empower these patients to 
participate actively in the research process, by direct col-
laboration with the industry, with regulatory agencies, or 
with patient associations.89 The education of these expert 
patients could help to change the current situation, in which 
“experiential knowledge is often seen as less valuable than 
scientific knowledge”.90
Conclusion
There are many opportunities for patients to participate 
more actively in the entire research process. As has been 
noted throughout this paper, some of the proposals are 
relatively easy to put into practice (Table 1). The lack of 
implementation suggests that there are cultural barriers 
holding back the change process. The most urgent need 
is probably to change the relative emphases assigned to 
the ethical principles guiding the physician/investigator–
patient relationship. The classic relational model, based 
on the principle of beneficence, which in turn is based 
on the authority of the physician, may be responsible for 
the fact that research is performed for patients, but not 
with them. The therapeutic misconception, the absence of 
patients on IRBs, the poor quality of information provided 
to participants, and the low levels of patient participation 
in establishing research priorities and study design are all 
elements indicating that the benevolence principle pre-
dominates in the research field.
For the changes described to become realities, physician/
investigator–patient relationships should be based on the 
principles of autonomy and non-maleficence. Moreover, there 
can be no autonomy as long as patients lack the information 
they need. Providing the population with more information 
Table 1 Specific initiatives to engage patients in the research process
identifying research priorities James Lind Alliance (http://www.jla.nihr.ac.uk/)
PCORi (www.pcori.org)
Leading and designing research PatientsLikeMe (www.patientslikeme.com)
23andMe (www.23andMe.com)
OMeRACT (www.omeract.org)
improving access to clinical trials european Union (www.clinicaltrialsregister.eu)
Trials 4 Me (http://trials4me.lillycoi.com/)
NiH (https://clinicaltrials.gov/)
Adequate information about the study Readability of informed consent documents and patient information sheets
Assessing patients’ experience Systematic collection of opinions and experiences of the participants
informing participants about the study results Process to communicate the results at the end of the study
Disseminating and applying research findings Promoting transparency
Databases of randomized clinical trials
information for patients in medical journals
information and education FDA (www.fda.gov/ForPatients)
NiH (www.nih.gov/health/clinicaltrials/index.htm)
ASCO (www.cancer.net/)
Oxford University (www.healthtalkonline.org/)
eUPATi (www.patientsacademy.eu)
Abbreviations: eUPATi, european Patients’ Academy on Therapeutic innovation; FDA, Food and Drug Administration; NiH, National institute of Health; PCORi, Patient-
Centered Outcomes Research institute; OMeRACT, outcome measures in rheumatoid arthritis clinical trials; ASCO, American Society of Clinical Oncology.
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about the aims of research will help to normalize the process, 
generating trust and promoting participation in research. 
There must be improvement in the quality of information 
provided to participants, and promotion of the emergence of 
the expert patient: one who can become actively involved in 
all of the activities described in this paper and who is capable 
of properly representing the interests of other patients.
Disclosure
JAS, RK and AF are employees of Lilly Spain. The opinions 
and ideas expressed in this article are personal and do not 
necessarily represent those of the company. The authors 
report no other conflicts of interest in this work.
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